Business

Mumbai-based Elder Pharmaceuticals has announced the introduction of a line of over-the-counter “inhalers for nasal congestion.” The intranasal products will be sold under the Solo brand, a range of products that also includes a pain… Read more . . .

Dance Biopharm has announced the completion of a $9.5 million private placement that will fund clinical trials of its Dance 501 inhaled insulin. The Phase 2 program for Dance 501 is complete, according to the… Read more . . .

Lupin Pharmaceuticals has announced the launch of the InspiraChamber valved holding chamber after it acquired exclusive US rights to the device from InspiRX. The InspiraChamber is being sold as part of a package with pediatric… Read more . . .

The United States Court of Appeals for the Federal Circuit has granted AstraZeneca’s request for a temporary injunction stopping Actavis from further sales of its budesonide inhalation suspension, according to Actavis. AstraZeneca has appealed the… Read more . . .

Lupin Limited and Polish biopharmaceutical company Celon Pharma have announced that they will co-develop a generic version of GSK’s Advair Diskus. Celon, which currently markets a fluticasone/salmeterol DPI called Salmex in Poland, will supply the… Read more . . .

Actavis has announced that after the United States District Court for the District of New Jersey denied AstraZeneca’s request for a permanent injunction and ruled that US Patent No. 7,524,834 is invalid, Actavis launched its… Read more . . .

GSK has relied heavily on social media to get out the word that its Flonase fluticasone propionate nasal spray is now available over the counter in the United States. The FDA approved Flonase OTC in… Read more . . .

Innovus Pharmaceuticals has announced that the acquisition of Novalere FP and its FlutiCare fluticasone propionate nasal spray. According to documents related to the merger filed with the US Securities and Exchange Commission (SEC), Novalere FP… Read more . . .

AstraZeneca will pay Actavis $600 million plus royalties for US and Canadian rights to Daliresp roflumilast and the Tudorza Pressair aclidinium bromide DPI, plus development rights to an aclidinium/formoterol DPI which was approved in Europe… Read more . . .